Plant Name: Phellodendron chinense
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| DRD1; ADORA2A; ADRA2C; ADRA2B; DRD2; CHRM1; HTR2B; HTR2C; | |
| GAA; BCHE; ACHE; | |
| GLA; FAAH; TERT; PKM; AKR1B1; AKR1B10; ALOX15; ALDH1A1; | |
| MAPK1; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA5A; CA4; CA6; CA3; | |
| PPARA; PPARD; PPARG; | |
| KDM4E; | |
| MAOA; PTGS2; PTGS1; XDH; | |
| CASP1; CASP7; | |
| HIF1A; | |
| SLC47A1; | |
| HTT; RAB9A; NPC1; LMNA; RAD52; FABP5; SIGMAR1; F3; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLC47A1 | Multidrug and toxin extrusion protein 1 | Q96FL8 | CHEMBL1743126 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAD52 | DNA repair protein RAD52 homolog | P43351 | CHEMBL2362978 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.256E-09 | 8.819E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.781E-09 | 1.108E-06 | ADORA2A, CA2, CA7, DRD1, DRD2, HIF1A, HTT, MAPK1, NPC1, PTGS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.152E-09 | 2.549E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.715E-09 | 2.766E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4, PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.862E-09 | 3.494E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.742E-08 | 6.538E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.043E-08 | 7.539E-06 | ADORA2A, CA2, CA7, DRD1, DRD2, HIF1A, HTR2B, HTR2C, HTT, MAPK1, NPC1, PTGS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.301E-08 | 1.106E-05 | ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4, XDH |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.501E-07 | 6.483E-05 | ADORA2A, CA2, CA7, DRD1, DRD2, HTR2B, HTR2C, HTT |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.838E-07 | 1.106E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.273E-06 | 2.717E-04 | ACHE, ADORA2A, ADRA2C, BCHE, CASP1, DRD2, GLA, HTT, MAPK1, PKM, PPARG, PTGS2, RAB9A, RAD52, SMN1, SMN2, TERT, XDH |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 1.616E-06 | 3.259E-04 | ACHE, BCHE, DRD1, DRD2, PTGS2 |
| BP | GO:0007610; behavior | GO:0007612; learning | 3.996E-06 | 6.693E-04 | BCHE, DRD1, DRD2, HIF1A, HTT, PTGS2 |
| BP | GO:0008283; cell proliferation | GO:2000648; positive regulation of stem cell proliferation | 4.098E-06 | 6.811E-04 | DRD2, HIF1A, TERT, THPO |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 5.089E-06 | 8.395E-04 | AKR1B1, BCHE, CA2, CA9, CYP1A2, NPC1, PKM, PPARA, PPARG, PTGS2, TSHR |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 5.542E-06 | 8.809E-04 | CASP1, CASP7, F3, PPARG, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.145E-06 | 9.626E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.145E-06 | 9.626E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.194E-06 | 9.635E-04 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, PPARA, PPARD, PPARG |
| BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 6.764E-06 | 1.045E-03 | ADRA2B, DRD2, PPARA, PPARG, PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 7.971E-06 | 1.161E-03 | ADORA2A, DRD1, DRD2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 7.971E-06 | 1.161E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 8.052E-06 | 1.161E-03 | ACHE, ADORA2A, CASP1, DRD2, HIF1A, HTR2B, PPARD |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 8.759E-06 | 1.238E-03 | AKR1B10, ALDH1A1, CYP1A1, CYP1B1, PPARD |
| BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 9.246E-06 | 1.291E-03 | ADORA2A, BCHE, CASP7, DRD2, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 9.488E-06 | 1.291E-03 | PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 9.488E-06 | 1.291E-03 | ACHE, BCHE |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.040E-05 | 1.381E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.233E-05 | 1.608E-03 | CASP7, CYP1A1, CYP1B1, DRD1, MAPK1, NPC1, PPARG, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0044242; cellular lipid catabolic process | 1.587E-05 | 1.883E-03 | AKR1B10, CYP1B1, FAAH, FABP5, GLA, PPARD |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.773E-05 | 2.076E-03 | HIF1A, LMNA, PPARD, PTGS2, TERT |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.878E-05 | 2.176E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 1.925E-05 | 2.200E-03 | ACHE, ALOX15, CYP1A1, DRD2, PPARA, PPARD |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 2.129E-05 | 2.377E-03 | AKR1B1, ALDH1A1, CYP1A1, CYP1B1, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.165E-05 | 2.405E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4, DRD1, FAAH, PTGS1, PTGS2, RAB9A, SIGMAR1 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 2.249E-05 | 2.432E-03 | HIF1A, HTR2B, TERT |
| BP | GO:0040011; locomotion | GO:0030334; regulation of cell migration | 2.267E-05 | 2.432E-03 | CYP1B1, DRD1, DRD2, F3, HIF1A, LMNA, MAPK1, PPARD, PPARG, PTGS2, TERT |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 2.614E-05 | 2.685E-03 | CA12, CA2, CA7, DRD1, DRD2, HIF1A, HTR2B, HTR2C, HTT, MAPK1 |
| BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 2.738E-05 | 2.773E-03 | CYP1A2, MAPK1, NPC1, TERT |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.841E-05 | 2.799E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.841E-05 | 2.799E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.841E-05 | 2.799E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.841E-05 | 2.799E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.841E-05 | 2.799E-03 | ADRA2B, ADRA2C |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.878E-05 | 2.823E-03 | AKR1B1, CASP7, DRD1, MAPK1, PKM, PPARG, PTGS2, TSHR |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 3.128E-05 | 3.001E-03 | ADRA2B, ADRA2C, DRD2 |
| BP | GO:0009987; cellular process | GO:0045600; positive regulation of fat cell differentiation | 3.369E-05 | 3.176E-03 | HTR2C, PPARD, PPARG, PTGS2 |
| BP | GO:0008283; cell proliferation | GO:0048660; regulation of smooth muscle cell proliferation | 4.819E-05 | 4.205E-03 | AKR1B1, PPARD, PPARG, PTGS2, TERT |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 4.828E-05 | 4.205E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 5.505E-05 | 4.659E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 5.570E-05 | 4.659E-03 | DRD2, PPARA, PPARD, PPARG |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 5.626E-05 | 4.659E-03 | ADORA2A, BCHE, CYP1B1, DRD2, LMNA, PPARD, PPARG, PTGS2, TERT, XDH |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 5.670E-05 | 4.659E-03 | ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 5.670E-05 | 4.659E-03 | ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.670E-05 | 4.659E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.670E-05 | 4.659E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:0001936; regulation of endothelial cell proliferation | 5.785E-05 | 4.718E-03 | F3, HIF1A, HTR2B, PPARG, XDH |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 5.911E-05 | 4.803E-03 | CA2, CA7, DRD1, DRD2, HIF1A, HTR2B, HTR2C, HTT, MAPK1 |
| MF | Unclassified; | GO:0004872; receptor activity | 5.990E-05 | 4.849E-03 | ADORA2A, ADRA2B, ADRA2C, CHRM1, DRD1, DRD2, F3, HTR2B, HTR2C, NPC1, PPARA, PPARD, PPARG, SIGMAR1, TSHR |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 7.041E-05 | 5.575E-03 | ADORA2A, DRD1, DRD2 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 7.903E-05 | 6.103E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0007610; behavior | GO:0007628; adult walking behavior | 7.903E-05 | 6.103E-03 | DRD1, DRD2, NPC1 |
| CC | GO:0044464; cell part | GO:0044463; cell projection part | 8.415E-05 | 6.430E-03 | ADORA2A, ADRA2C, AKR1B1, CA4, CA9, CHRM1, DRD1, DRD2, HIF1A, MAPK1, PTGS1, SIGMAR1 |
| BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 8.832E-05 | 6.564E-03 | DRD1, DRD2, MAOA |
| BP | GO:0050896; response to stimulus | GO:0006979; response to oxidative stress | 9.015E-05 | 6.677E-03 | AKR1B1, CA3, CYP1B1, MAPK1, PTGS1, PTGS2, RAD52 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 9.432E-05 | 6.756E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 9.432E-05 | 6.756E-03 | HTR2B, HTR2C |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 9.432E-05 | 6.756E-03 | PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.432E-05 | 6.756E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0072330; monocarboxylic acid biosynthetic process | 9.601E-05 | 6.832E-03 | ALOX15, CYP1A1, PKM, PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 1.006E-04 | 6.999E-03 | AKR1B1, CASP1, CYP1B1, DRD1, MAPK1, PKM, PPARD, PPARG, PTGS2, TSHR |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.012E-04 | 6.999E-03 | ADORA2A, ADRA2B, ADRA2C, CHRM1, DRD1, DRD2, F3, HTR2B, HTR2C, NPC1, PPARG, SIGMAR1, TSHR |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.158E-04 | 7.878E-03 | CYP1B1, F3, HIF1A, PTGS2, TERT |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 1.158E-04 | 7.878E-03 | ADORA2A, DRD1, DRD2, MAPK1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0010039; response to iron ion | 1.204E-04 | 8.141E-03 | CYP1A1, DRD2, HIF1A |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 1.243E-04 | 8.364E-03 | ADORA2A, CASP1, DRD2, F3, HIF1A, LMNA, MAPK1, PPARA, PPARD, PPARG, PTGS2, RAD52, TERT, XDH |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.245E-04 | 8.364E-03 | CA4, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, CYP3A4, DRD1, DRD2, FAAH, FABP5, GAA, HTT, LMNA, MAOA, NPC1, PTGS1, PTGS2, RAB9A, SIGMAR1 |
| BP | GO:0008152; metabolic process | GO:0052652; cyclic purine nucleotide metabolic process | 1.325E-04 | 8.746E-03 | ADORA2A, HTR2B, HTR2C |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 1.412E-04 | 9.042E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 1.412E-04 | 9.042E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.412E-04 | 9.042E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.412E-04 | 9.042E-03 | CA1, CA2 |
| BP | GO:0009987; cellular process | GO:0060548; negative regulation of cell death | 1.492E-04 | 9.442E-03 | ADORA2A, AKR1B1, HIF1A, HTR2B, HTT, LMNA, NPC1, PPARA, PPARD, PTGS2, TERT |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.126E-22 | 2.451E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.685E-17 | 6.304E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.268E-15 | 5.520E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.125E-22 | 8.252E-20 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.550E-11 | 3.663E-09 | CYP2D6; MAOA; ALOX15; HTR2B; HTR2C; MAPK1; CYP2C19; PTGS2; PTGS1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.313E-07 | 6.661E-06 | CHRM1; ADORA2A; HTR2B; HTR2C; DRD1; ADRA2C; DRD2; ADRA2B; TSHR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.655E-07 | 6.661E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.148E-06 | 4.322E-05 | CHRM1; ADORA2A; MAPK1; DRD1; PPARA; DRD2; TSHR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.989E-06 | 4.322E-05 | MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.633E-06 | 4.711E-05 | CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.643E-06 | 4.322E-05 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.342E-05 | 1.801E-04 | MAOA; GAA; ALOX15; AKR1B1; PTGS2; CYP2C19; CYP3A4; PTGS1; PKM; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.892E-06 | 4.322E-05 | AKR1B10; GAA; AKR1B1; GLA |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.169E-06 | 9.713E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 6.636E-06 | 9.713E-05 | HTR2B; HTR2C; MAPK1; DRD1; DRD2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.584E-05 | 4.122E-04 | ALOX15; CYP2C19; PTGS2; PTGS1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.751E-05 | 3.407E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.321E-05 | 4.638E-04 | CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 2.044E-04 | 1.732E-03 | CHRM1; ADORA2A; HTR2B; HTR2C; DRD1 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 1.991E-04 | 1.732E-03 | ADORA2A; MAOA; MAPK1; DRD1; DRD2 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.469E-05 | 5.503E-04 | FABP5; PPARG; PPARA; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.551E-04 | 3.489E-03 | CYP1A1; CYP1B1; PTGS2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 6.354E-04 | 4.650E-03 | PTGS2; TSHR; PTGS1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.287E-04 | 3.451E-03 | MAOA; DRD1; DRD2 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 7.405E-04 | 5.183E-03 | AKR1B10; AKR1B1; GLA |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.073E-03 | 7.196E-03 | PKM; MAPK1; HIF1A |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 3.472E-03 | 1.996E-02 | FAAH; MAPK1; PTGS2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 4.525E-03 | 2.350E-02 | ACHE; CHRM1; MAPK1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.487E-03 | 9.574E-03 | CASP7; CASP1; MAPK1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.412E-03 | 2.350E-02 | CASP7; MAPK1; PTGS2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.712E-03 | 3.157E-02 | MAPK1; PPARG; PTGS2; HIF1A; PPARD |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 6.018E-03 | 2.936E-02 | NPC1; GAA; GLA |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.588E-03 | 3.737E-02 | CASP7; LMNA; MAPK1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 6.863E-03 | 3.157E-02 | MAOA; DRD1; DRD2 |
| hsa05012 | Parkinson's disease_Homo sapiens_hsa05012 | 8.926E-03 | 3.772E-02 | ADORA2A; DRD1; DRD2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.271E-02 | 4.871E-02 | MAPK1; PPARD |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.411E-03 | 1.996E-02 | MAPK1; PPARG |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.187E-02 | 4.777E-02 | CASP7; CASP1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.271E-02 | 4.871E-02 | CASP1; MAPK1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 9.137E-03 | 3.772E-02 | PKM; MAPK1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 8.416E-03 | 3.737E-02 | CYP3A4; XDH |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 4.143E-03 | 2.300E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 5.222E-03 | 2.627E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.150E-03 | 1.331E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.799E-05 | 8.333E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
| NA: NA | Dystonia | NA | CHRM1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2C; MAOA |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| NA: NA | Excessive sweating | NA | CHRM1 |
| NA: NA | Hyperaemia | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADRA2C; DRD2; DRD2; DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; MAOA; DRD2; PPARG; PPARG; ACHE; ACHE; ACHE; PTGS2; CHRM1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| NA: NA | Functional bowel syndrome | NA | CHRM1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1; DRD2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| NA: NA | False perceptions | NA | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| NA: NA | Corneal vascularity | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2C; DRD2; DRD2; DRD2; DRD2; CHRM1; CHRM1; CHRM1; DRD1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Schizoaffective disorders | NA | DRD2; CHRM1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; CASP1; PTGS2; PTGS2; PTGS2; PTGS2 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9; MAPK1; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; DRD2; CHRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| NA: NA | Itching | NA | DRD2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM1; HTR2B |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; DRD2; CYP2D6 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA2A; CA1; CA1; AKR1B1; ADRA2C; DRD2; ACHE; CHRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; DRD2; DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2B; CYP2D6 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| NA: NA | Vomiting | NA | DRD2 |
| NA: NA | Primary insomnia | NA | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; DRD2; PTGS1; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; PPARG; PTGS1; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD; PPARG; PPARG; PTGS2; DRD1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2A; ADRA2C; DRD2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; ADRA2C; CHRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADRA2B; MAOA; PTGS1; PTGS2; PTGS2; CHRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PPARG; PTGS2 |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR2C; PPARD; PPARD; ADRA2C; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; HTR2C; HTR2C; MAOA; MAOA; DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1 |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; CHRM1; DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; MAOA; DRD2; ACHE; CHRM1; CHRM1; DRD1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; F3; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; FAAH; HTR2C; ADRA2C; DRD2; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PKM; DRD1 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; CHRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2C; AKR1B1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2C; ADRA2C; MAOA; HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH; HTR2C; CYP3A4; MAOA; DRD2; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2; DRD1 |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; TERT; DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH; CHRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; PPARG |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA1; CA9; MAPK1; ACHE; PTGS2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| NA: NA | Abdominal stomach pain | NA | CHRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2C; ADRA2C; ADRA2B; MAOA; DRD2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG; PTGS2 |